Posts Tagged ‘biotech’

The cost and affordability of drugs has been a central theme permeating the pharmaceutical industry for decades. Drugs are believed to be too expensive for patients to cover at the counter, even for those who are insured. The sentiment shared is by both Republicans and Democrats. The high cost of drugs can have significant repercussions, […]

With Appian. Yes, Appian. “I have no idea what that is…” Yes, I can read your mind. Okay, okay, I’m not actually clairvoyant. But I do have a pretty good sense of the industry, and I know that Appian hasn’t become a household name, yet. But, the times they are a-changin’. Appian is a business […]

The United States is known for massive innovation across sectors, especially in the pharmaceutical arena. According to the Pharmaceutical Research and Manufacturers of America, in 2015 member companies of the advocacy organization invested more than $58 billion in research and development, making the pharmaceutical industry the largest investor in research and development of any sector. […]

If that title compelled you to open this post, then you know what 21 CFR Part 11 is, and you also know – as my 12-year-old step daughter would say – “the struggle is real.” 21 CFR Part 11 is perhaps the most famous (or infamous!) regulation published by the U.S. Food and Drug Administration […]

Now that April is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in March – they’re ranked in order of popularity, with number one being the most viewed piece. Oh My, Where Has The Time Gone? […]

Recently, one of our Oracle Siebel Clinical Trial Management System (CTMS) clients noted that the rollups feature, which collates information from lower levels of the data type hierarchy into a single view (e.g., all site records within a single region or country), was not working properly. Specifically, the fields that indicate the number of subjects […]

Life sciences is one of the most heavily regulated industries in the United States. It takes 10 to 15 years and an average of $2.6 billion for a drug to reach pharmacy shelves. Stringent regulations formed by the FDA are major factors for the lengthy timelines and high costs, sometimes preventing people from receiving potentially […]

Many moons ago, I wrote the blog post This Is Bad News For Sponsors And CROs, in which I shared how the number of principal investigators interested in running new trials had declined. Another blog post from several several years ago, Wait, You’re Not Using an Investigator Portal?, shared one method of increasing satisfaction among […]

The fourth year of Oracle Industry Connect (OIC) was, overall, an absolute success. Several thousand attendees from around the world and a variety of industries met in Orlando to learn about the latest trends in technology and to hear firsthand how companies have been able to streamline and strengthen their businesses with software solutions from […]

I thought it might be helpful to provide instruction on how I set up each virtual machine to support the Oracle Siebel Clinical Trial Management System (CTMS) implementation and integration projects I work on. As I mentioned in a previous post, I have a clone master for each version of Siebel that I keep offline […]

The idea of companies moving their businesses to other parts of the world to benefit from lower taxes is not new. Allergan, the maker of Botox® and other drugs, transferred its global headquarters from New Jersey to Ireland in 2013. Medtronic moved its headquarters to Ireland in 2015, once it completed the acquisition of Covidien, […]

While Siebel developers have always been encouraged to use non-scripting solutions to implement custom business functionality, almost every Siebel Clinical (CTMS) implementation project that I have worked on has included an integration component, and in almost every instance, it has required some coding with Siebel eScript. But, how do you debug your custom code? For […]